Association of Disease-Modifying Treatment and Anti-CD20 Infusion Timing With Humoral Response to 2 SARS-CoV-2 Vaccines in Patients With Multiple Sclerosis.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 34554185.
- Also identified by DOI 10.1001/jamaneurol.2021.3609 and PMC identifier 8461551.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This cohort study investigates the humoral response to 2 SARS-CoV-2 messenger RNA vaccines in patients with multiple sclerosis treated with fingolimod and ocrelizumab.
Medical subject headings
- Antibodies, Monoclonal
- Antigens, CD20
- COVID-19
- COVID-19 Vaccines
- Immunity, Humoral
- Multiple Sclerosis